



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Shaw-Fen Sylvia Hu

Serial No.:

09/687,993

Filed:

October 13, 2000

For:

Truncated Glial Cell Line-Derived Neurotrophic Factor

RECEIVED

Docket No.:

A-357C

AUG 0 4 2003

## ATTORNEY'S STATEMENT PURSUANT TO 37 CFR § 1.821

TECH CENTER 1600/2900

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir

I hereby state that the amended paper copy and the amended computer readable form (CRF) of the "Sequence Listing" submitted herewith for the above-mentioned patent application are the same.

The sequence listing submitted herewith contains no new matter.

Respectfully submitted,

Robert L. Sharp

Attorney/Agent for Applicant(s)

Registration No.:45,609 Phone: (805) 447-5992 Date: July 29, 2003

Please send all future correspondence to:

U.S. Patent Operations/RLS Dept. 4300, M/S 27-4-A AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1799

## **EXPRESS MAIL CERTIFICATE**

"Express Mail" mail tabeling number:

EL360691995US

ate of Deposit: July 29, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail PosyOffice to Addressee" service upder 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria WA 283 31450.

Lyane Du

Suchsbaum intel Name

Addressee's service under 37 C.F.R. 1.10 on the date